De Burlo Group’s Salix Pharmaceuticals SLXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
– Sell
-3,100
Closed -$535K – 112
2015
Q1
$535K Sell
3,100
-200
-6% -$29.4K 0.11% 81
2014
Q4
$379K Sell
3,300
-78,900
-96% -$9.6M 0.08% 90
2014
Q3
$12.8M Buy
82,200
+4,700
+6% +$681K 2.84% 5
2014
Q2
$9.6M Buy
77,500
+5,400
+7% +$597K 2.16% 14
2014
Q1
$7.47M Buy
+72,100
New +$7.38M 1.8% 20

Other funds holding SLXP

De Burlo Group's SLXP Position: Q2 2015 in Review

De Burlo Group sold out of Salix Pharmaceuticals (SLXP) in Q2 2015, closing a stake of 3,100 shares — an estimated $535K sold.

De Burlo Group first reported a position in SLXP in Q1 2014 and held it in 5 quarters. The position peaked at $12.8M in Q3 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • De Burlo Group reported no remaining Salix Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • De Burlo Group sold 3,100 Salix Pharmaceuticals shares in Q2 2015, an estimated $535K.
  • De Burlo Group first reported a position in Salix Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • De Burlo Group's Salix Pharmaceuticals position peaked at $12.8M in Q3 2014.
  • 1 fund tracked by Wall St. Rank held Salix Pharmaceuticals as of Q2 2015.

Based on De Burlo Group's 13F filing for Q2 2015, filed 7 Aug 2015.